TY - JOUR
T1 - The digital transformation of hepatology
T2 - The patient is logged in
AU - Wu, Tiffany
AU - Simonetto, Douglas A.
AU - Halamka, John D.
AU - Shah, Vijay H.
N1 - Funding Information:
Various frameworks have been offered for evaluating health technology development. Clinician leaders have outlined priorities such as privacy, security, need for evidence, ease of use, and data integration in a bottom‐up approach that encourages dialogue regarding unique patient situations and preferences. With funding support from the Moore Foundation, a consortium led by Mayo Clinic will soon address standardization of AI labeling and validation schema regarding the characteristics, behavior, efficacy, and equity of health AI systems. Different stakeholders in industry and government have also identified broad guidelines for technology evaluation. For instance, the Xcertia collaborative among organizations such as the American Medical Association, American Heart Association, Healthcare Information and Management Systems Society, and DHX Group published guidelines for mobile app development standards to ensure data privacy, security, usability, interoperability, and content. In government, the United Kingdom’s National Health Service oversees the Digital Apps Library to score various mobile health apps on overlapping measures of clinical effectiveness, safety, privacy, security, interoperability, and other metrics. The need for a rigorous and cohesive validation system has further prompted a proposal by Simon Mathews and colleagues for a Digital Health Scorecard, which outlines a pragmatic framework for assessment of technical performance, clinical function, usability, and cost impact of solutions at all stages in the care continuum. Though the path to validation poses conceptual, financial, and operational challenges to implementation, a systematic requirements‐driven approach is necessary to guide high‐quality innovation. [ 78 ] [ 79 ] [ 80 ] [ 81 ] [ 81 ]
Publisher Copyright:
© 2022 American Association for the Study of Liver Diseases.
PY - 2022/3
Y1 - 2022/3
N2 - The rise in innovative digital health technologies has led a paradigm shift in health care toward personalized, patient-centric medicine that is reaching beyond traditional brick-and-mortar facilities into patients’ homes and everyday lives. Digital solutions can monitor and detect early changes in physiological data, predict disease progression and health-related outcomes based on individual risk factors, and manage disease intervention with a range of accessible telemedicine and mobile health options. In this review, we discuss the unique transformation underway in the care of patients with liver disease, specifically examining the digital transformation of diagnostics, prediction and clinical decision-making, and management. Additionally, we discuss the general considerations needed to confirm validity and oversight of new technologies, usability and acceptability of digital solutions, and equity and inclusivity of vulnerable populations.
AB - The rise in innovative digital health technologies has led a paradigm shift in health care toward personalized, patient-centric medicine that is reaching beyond traditional brick-and-mortar facilities into patients’ homes and everyday lives. Digital solutions can monitor and detect early changes in physiological data, predict disease progression and health-related outcomes based on individual risk factors, and manage disease intervention with a range of accessible telemedicine and mobile health options. In this review, we discuss the unique transformation underway in the care of patients with liver disease, specifically examining the digital transformation of diagnostics, prediction and clinical decision-making, and management. Additionally, we discuss the general considerations needed to confirm validity and oversight of new technologies, usability and acceptability of digital solutions, and equity and inclusivity of vulnerable populations.
UR - http://www.scopus.com/inward/record.url?scp=85123948376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123948376&partnerID=8YFLogxK
U2 - 10.1002/hep.32329
DO - 10.1002/hep.32329
M3 - Review article
C2 - 35028960
AN - SCOPUS:85123948376
SN - 0270-9139
VL - 75
SP - 724
EP - 739
JO - Hepatology
JF - Hepatology
IS - 3
ER -